This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
Global Pandemic Financing

World Bank Board Approves New Fund for Pandemic Prevention, Preparedness and Response (PPR)

World Bank to work together with WHO to set up Secretariat at the World Bank, with WHO as lead technical partner

WASHINGTON, June 30, 2022— The devastating human, economic, and social cost of COVID-19 has highlighted the urgent need for coordinated action to build stronger health systems and mobilize additional resources for pandemic prevention, preparedness, and response (PPR).

The World Bank’s Board of Executive Directors today approved the establishment of a financial intermediary fund (FIF) that will finance critical investments to strengthen pandemic PPR capacities at national, regional, and global levels, with a focus on low- and middle-income countries. The fund will bring additional, dedicated resources for PPR, incentivize countries to increase investments, enhance coordination among partners, and serve as a platform for advocacy. The FIF will complement the financing and technical support provided by the World Bank, leverage the strong technical expertise of WHO, and engage other key organizations.

Developed with leadership from the United States, and from Italy and Indonesia as part of their G20 Presidencies, and with broad support from the G20 and beyond, over $1 billion in financial commitments have already been announced for the FIF, including contributions from the United States, the European Union, Indonesia, Germany, the United Kingdom, Singapore, the Gates Foundation and the Wellcome Trust.

“I’m pleased by the broad support from our shareholders for a new Financial Intermediary Fund at the World Bank,” World Bank Group President David Malpass said. “The World Bank is the largest provider of financing for PPR with active operations in over 100 developing countries to strengthen their health systems. The FIF will provide additional, long-term funding to complement the work of existing institutions in supporting low- and middle-income countries and regions to prepare for the next pandemic.”

“Access to financing for pandemic prevention and preparedness is crucial. COVID-19 has exposed major gaps in preparedness capacities, which the Financial Intermediary Fund can address in a coherent manner, as part of the global architecture for health emergency preparedness and response,” said WHO Director General Dr Tedros Adhanom Ghebreyesus. “WHO will play a central role in the FIF, providing technical leadership for its work in close collaboration with the World Bank to realize this ambitious vision.”

The goal of the FIF is to provide financing to address critical gaps in pandemic PPR to strengthen country capacity in areas such as disease surveillance, laboratory systems, health workforce, emergency communication and management, and community engagement. It
can also help address gaps in strengthening regional and global capacity, for example, by supporting data sharing, regulatory harmonization, and capacity for coordinated development, procurement, distribution and deployment of countermeasures and essential medical supplies.

In the coming weeks, the Bank and WHO will work closely with donors and other partners to develop the detailed scope and design of the FIF. The ongoing discussions will be informed by the extensive inputs provided through stakeholder engagement (LINK). The goal is to launch the FIF in fall 2022...

Fact Sheet: Financial Intermediary Fund for Pandemic Prevention, Preparedness and Response
Date: June 30, 2022 Type: Brief

Featured Journal Content

PNAS - Proceedings of the National Academy of Sciences of the United States
June 21, 2022 | vol. 119 | no. 25

Research Article  June 13, 2022Coronavirus (COVID-19)
Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic
The fragmented and inefficient healthcare system in the United States leads to many preventable deaths and unnecessary costs every year. Universal healthcare could have alleviated the mortality caused by a confluence of negative COVID-related factors. Incorporating the demography of the uninsured with age-specific COVID-19 and nonpandemic mortality, we estimated that a single-payer universal healthcare system would have saved 212,000 lives in 2020 alone. We also calculated that US$105.6 billion of medical expenses associated with COVID-19 hospitalization could have been averted by a Medicare for All system.

Significance
The fragmented and inefficient healthcare system in the United States leads to many preventable deaths and unnecessary costs every year. Universal healthcare could have alleviated the mortality caused by a confluence of negative COVID-related factors. Incorporating the demography of the uninsured with age-specific COVID-19 and nonpandemic mortality, we estimated that a single-payer universal healthcare system would have saved 212,000 lives in 2020 alone. We also calculated that US$105.6 billion of medical expenses associated with COVID-19 hospitalization could have been averted by a single-payer universal healthcare system.
over the course of the pandemic. These economic benefits are in addition to US$438 billion expected to be saved by single-payer universal healthcare during a nonpandemic year.

---

**Featured Journal Content**

*Science*
Volume 377| Issue 6601| 1 Jul 2022
https://www.science.org/toc/science/current

*Editorial*

**Science, health, and truth**
BY William L. Roper
30 Jun 2022

The past 2 years have been a strange and difficult time for the world. The COVID-19 pandemic has brought illness, hospitalization, and death near to many people. In the United States, people are divided not only on what they should do but also on what constitutes the facts.

Many are seemingly in an alternative world, driven by disinformation, conspiracy theories, and anti-science beliefs. How can health and medical leaders do their jobs while trying to cope with a polarized public? They must be more effective in explaining and persuading the public on matters of science and health. This will require better clarification of two things to the public—the roles of science and politics in public policy decisions, and the means by which scientific truth is established and updated.

There is a continuing strand of argument from many in the scientific community that “we ought to get politics out of public health.” And many politicians have said that scientists are not the ones to make public policy decisions related to public health or other issues. **The reality is that both science and politics are essential for public health to work well.** Scientists inform public understanding of the patterns of health and illness in populations, especially when epidemics and pandemics strike. And politics—the way decisions are made in a democratic society—is vital for acting on the information and insights that the scientific community provides for the benefit of everyone.

In addition to clarifying the separate roles of science and politics, society needs to understand better how scientific truth is established and updated. It is based on verified and reproducible facts. The scientific method of gathering data, debating various formulations of the information, and arriving at consensus understandings of what is “true” about a particular matter has been the bedrock for establishing scientific truth for centuries. But in the past few years, political leaders, media personalities, and ordinary citizens have proclaimed their own “alternative facts,” disparaging the idea that anyone should question their “facts” and theories.

In his recent book, *The Constitution of Knowledge: A Defense of Truth*, Jonathan Rauch clearly and convincingly describes and defends the Enlightenment-born process of weighing evidence and committing to truth. He explains that the endeavor is founded on two arguments: The truth is based on what is known so far and the truth applies to everyone. **Rauch argues that this has produced a process for certifying knowledge—a public system for adjudicating differences of belief**
and perception and for developing shared and warranted conclusions about truth. This system provides three public goods: knowledge (distinguishing reality from nonreality), freedom (encouraging rather than repressing human autonomy, creativity, and empowerment), and peace (rewarding social conciliation, maximizing the number of disagreements that are resolvable, and compartmentalizing and marginalizing disagreements that cannot be resolved).

Given that truth is based on what is known so far, it is always provisional. We likely will know more tomorrow than today, and we will then have to revise our conclusions. That is just the scientific method at work. Though science and politics have separate roles, once this system “gets the facts straight,” scientists and political leaders can work constructively together for the common good.

This knowledge-certifying system is under concerted attack today, most notably in polarized political conflicts, including about masks and vaccines, climate change, and gun violence. Restoring confidence in messages regarding science for the public good will be challenging, but it can only be done if there is an effort to explain, defend, and reinforce this public system for shepherding new knowledge. This needs to include widespread discussions across the scientific community and in the public at large, leading to a broad recommitment to the scientific method.

The challenges of communicating messages about science, health, and truth are among the often-mentioned reasons for the fatigue and discouragement that public health and medical leaders face today. And that same frustration is transferred to those who seek to engage the wider public with these messages.

Overcoming these challenges will surely be difficult, but with concerted effort it can be done, as it has before—for example, in efforts to promote widespread childhood immunizations. And this requires a never-ending commitment, as we are learning every day.

::::
::: :

Featured Journal Content

American Journal of Therapeutics
June 20, 2022
Original Investigation

Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study
Sheldrick, Kyle A. MBBS1,*; Meyerowitz-Katz, Gideon MPH2; Tucker-Kellogg, Greg PhD3
doi: 10.1097/MJT.0000000000001528

Abstract
Background:
Multiple vaccines against Covid-19 have passed through phase-3 trials; however, concerns have been raised about alleged excessive similarity of efficacy across age groups for the Sputnik V vaccine.

Study Question:
How likely are the observed efficacies for all age subgroups to fall within the range of by-age efficacies claimed for the AstraZeneca, Janssen, Moderna, Pfizer, and Sputnik V vaccines, assuming that there is no effect of age on efficacy?
Study Design:
We performed a simulation study using R of 1000 and then 50,000 simulated trials for each vaccine, with random allocation to each arm but fixed enrollment numbers by age group. We used study-wide efficacy and infection rate for all age groups. We recorded the observed vaccine efficacies in each age group and summated how many simulations had all observed efficacies fall within the range of efficacies described in the relevant article.

Results:
In the 1000-trial simulation for the AstraZeneca vaccine, in 23.8% of simulated trials, the observed efficacies of all age subgroups fell within the efficacy bounds for age subgroups in the published article. The J + J simulation showed 44.7%, Moderna 51.1%, Pfizer 30.5%, and 0.0% of the Sputnik simulated trials had all age subgroups fall within the limits of the efficacy estimates described by the published article. In 50,000 simulated trials of the Sputnik vaccine, 0.026% had all age subgroups fall within the limits of the efficacy estimates described by the published article, whereas 99.974% did not.

Conclusions:
The distribution of alleged vaccine efficacies of the Sputnik vaccine by age in the phase-III trial is very unlikely to occur in genuine experimental data, even if the number of patients recruited, vaccine efficacy, and overall infection rate are true and there is no underlying difference in vaccine efficacy by age.

::::::

African Development Bank’s Board approves landmark institution: Establishment of African Pharmaceutical Technology Foundation to transform Africa’s pharmaceutical industry
27-Jun-2022 - The African Development Bank’s Board of Directors has approved the establishment of the African Pharmaceutical Technology Foundation, a new groundbreaking institution that will significantly enhance Africa’s access to the technologies that underpin the manufacture of medicines, vaccines, and other pharmaceutical products...

The African Pharmaceutical Technology Foundation...when fully established will be staffed with world-class experts on pharmaceutical innovation and development, intellectual property rights, and health policy; acting as a transparent intermediator advancing and brokering the interests of the African pharmaceutical sector with global and other Southern pharmaceutical companies to share IP-protected technologies, know-how and patented processes.

African Development Bank Group President, Dr. Akinwumi Adesina said: “Even with the decision of the TRIPS Waiver at the World Trade Organization (WTO), millions are dying -and will most likely continue to die - from lack of vaccines and effective protection. The African Pharmaceutical Technology Foundation provides a practical solution and will help to tilt the access to proprietary technologies, knowledge, know-how and processes in favor of Africa”.

The World Trade Organization and the World Health Organization, respectively, welcomed and lauded the African Development Bank’s decision to establish the African Pharmaceutical Technology Foundation...

::::::
COVID Perspectives

**S.Korea approves first domestically developed COVID vaccine**

SEOUL, June 29 (Reuters) - South Korea approved its first domestically developed COVID-19 vaccine, manufactured by SK bioscience Co Ltd, for general public use following positive clinical data, authorities said on Wednesday.

The SKY Covione vaccine was authorised for a two-dose regimen on people aged 18 or older, with shots given four weeks apart, according to the Ministry of Food and Drug Safety.

In a phase III clinical trial of 4,037 adults, SKY Covione induced neutralizing antibody responses against the SARS-CoV-2 parental strain, SK bioscience said in a statement.

It is not yet known how effective it is against Omicron and other COVID variants.

The vaccine was jointly developed by the University of Washington's Institute for Protein Design, with the support of global drugmaker GlaxoSmithKline (GSK).

SK bioscience said it would seek authorisations for distribution of SKY Covione in other countries and through global vaccine sharing facility COVAX, and for emergency use listing at the World Health Organization...

**Kenya to woo vaccine firms with tax offer**

By EDWIN MUTAI

*The East African*

Thursday June 30 2022

Kenya has offered tax incentives to woo investors seeking to build factories for the manufacture of human vaccines including for Covid-19.

Investors with investments of at least Ksh10 billion ($85 million) will enjoy corporate and income taxes at exclusive rates to be negotiated with the government.

This is in line with changes to the law through the Finance Act, 2022 that President Uhuru Kenyatta signed into law last Friday.

Parliament amended the Income Tax Act, through the Finance Bill, 2022, to provide tax incentives to firms that will undertake local production of vaccines.

“A company which is engaged in business under a special operating framework arrangement with the government, incorporated for purposes of undertaking the manufacturer of human vaccines, whose capital investment is at least Sh10 billion, shall be subject to the rate of tax specified in the special operating framework arrangement with the government,” the Finance Act, 2022 states...

******

******

**Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

**Weekly Epidemiological and Operational updates**

Last update: 17 Jun 2022

**Confirmed cases**: 545 226 550

**Confirmed deaths**: 6 334 728

**Vaccine doses administered**: 11 986 040 938
Weekly epidemiological update on COVID-19 – 29 June 2022

Overview
Globally, the number of weekly COVID-19 cases has increased for the third consecutive week, after a declining trend was observed since the last peak in March 2022. During the week of 20 to 26 June 2022, over 4.1 million cases were reported, an 18% increase as compared to the previous week. The number of new weekly deaths remained similar to that of the previous week, with over 8500 fatalities reported.

In this edition we also provide:
:: An update on the circulating SARS-CoV-2 variants of concern (VOCs)
:: Special focus on relative vaccine effectiveness

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 26 June 2022**

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 02 July 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]
**Global Dashboard on COVID-19 Vaccine Equity**

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 02 July 2022]: https://data.undp.org/vaccine-equity/

See also visualization on [Vaccine Access](https://data.undp.org/vaccine-equity/) and [Vaccine Affordability](https://data.undp.org/vaccine-equity/)

---

**COVID-19 Global Targets and Progress Tracker** - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID-19 Vaccine Roll-out

02 July 2022 | COVAX (WHO, GAVI, CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 111M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 12.1B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 330M
Other Delivered (Number of Doses): 350M
Total Delivered (Number of Doses): 680M
Total Administered (Number of Doses): 440M
Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 02 July 2022: https://data.covid19taskforce.com/data. The global view below is complemented by country-specific dashboards here.
Our World in Data

**Coronavirus (COVID-19) Vaccinations**  [Accessed 02 July 2022]

:: 66.5% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.08 billion doses have been administered globally, and 5.73 million are now administered each day.
:: Only 17.6% of people in low-income countries have received at least one dose.
**U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**HHS**

*News*

**Biden-Harris Administration Announces Additional Deliveries of Vaccine as Part of Nationwide Vaccine Strategy for Preventing Monkeypox**
July 1, 2022 | News Release

**HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox Preparedness**
July 1, 2022 | News Release

**Biden-Harris Administration secures 105 million doses of Pfizer’s latest COVID-19 vaccine for fall vaccination campaign**
June 29, 2022 | News Release

**HHS Announces Enhanced Strategy to Vaccinate and Protect At-Risk Individuals from the Current Monkeypox Outbreak**
June 28, 2022 | News Release

**FDA**

*Press Announcements*


On Tuesday, the U.S. Food and Drug Administration’s independent experts on the Vaccines and Related Biological Products Advisory Committee met to publicly discuss whether a change to the current vaccine strain composition of COVID-19 vaccines for booster doses is necessary for the 2022 fall and winter seasons...

Following the vote, and striving to use the best available scientific evidence, we have advised manufacturers seeking to update their COVID-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine, so that the modified vaccines can potentially be used starting in early to mid-fall 2022.

As we expect this coming year to be a transitional period when this modified booster vaccine may be introduced, we have not advised manufacturers to change the vaccine for primary vaccination, since a primary series with the FDA-authorized and approved COVID-19 vaccines provides a base of protection against serious outcomes of COVID-19 caused by circulating strains of SARS-CoV-2...

...In keeping with our commitment to transparency, the FDA will communicate future plans pertaining to the potential authorization or approval of COVID-19 vaccine booster doses with an omicron component.

**Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**European Medicines Agency**
News & Press Releases

News: Global regulators agree on key principles on adapting vaccines to tackle virus variants (new)
Last updated: 01/07/2022

News: Assessing dietary exposure to residues of veterinary medicines, feed additives and pesticides in food of animal origin in the EU (new)
CVMP, Last updated: 30/06/2022

News: Call for companies to register their Industry Single Point of Contact (i-SPOC) on supply and availability (new)
Last updated: 28/06/2022

News: Monkeypox: EMA starts review for Imvanex (new)
CHMP, Last updated: 28/06/2022

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates [Selected]
News

Joint ECDC-WHO/Europe surveillance bulletin: Hepatitis of unknown origin in children
Epidemiological update - 30 Jun 2022

Weekly COVID-19 country overview
Epidemiological update - 30 Jun 2022

Joint ECDC-WHO Europe COVID-19 surveillance bulletin
Epidemiological update - 30 Jun 2022

ECDC launches e-learning course on how to address online vaccination misinformation
News - 29 Jun 2022

Publication
Considerations for contact tracing during the monkeypox outbreak in Europe, 2022
Guidance - 28 Jun 2022

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Latest [Selected]
Press release 28 June 2022
European Health Union: Start of delivery of vaccines in response to the monkeypox outbreak
Today, the delivery of the first vaccine doses purchased by the European Commission's Health Emergency Preparedness and Response Authority (HERA) in response to the current monkeypox
outbreak is starting, with an initial 5,300 doses arriving in Spain, out of the total 109,090 doses procured.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified.

Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study
Sheldrick, Kyle A. MBBS1,*; Meyerowitz-Katz, Gideon MPH2; Tucker-Kellogg, Greg PhD3
American Journal of Therapeutics, June 20, 2022
doi: 10.1097/MJT.0000000000001528
[See Featured Journal Content above for abstract]

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/
Government of India – Press Information Bureau

Latest Press Releases

COVID - 19 Vaccination Update - Day 533
:: India’s cumulative vaccination coverage crosses 197.94 Crore
:: More than 8 lakh Vaccine doses administered today till 7 pm
Posted On: 02 JUL 2022 8:37PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html

Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations, leading us to include these reports/observations from the general media below. See China CDC below for additional announcements]

China eases Covid entry restriction to allow transit via third country
:: A notice from the Chinese embassy in the US says travellers can now get health codes needed to board flights when travelling to China via third countries
:: News is likely to reduce burden on businesses and follows a move to reduce quarantine requirements earlier this week
He Huifeng in Guangdong
South China Morning Post, Published: 7:30pm, 2 Jul, 2022

:::
:::

GPEI - Polio

Polio this week as of 28 June 2022
Headlines
Global leaders at the G7 and Commonwealth leaders meetings this week call for strengthened support to end polio once and for all. ARCC outcomes – As south-east Africa continues to intensify efforts to stop a wild poliovirus type 1 (WPV1) outbreak detected in Malawi in February, the Africa Regional Certification Commission for Polio Eradication (ARCC) – the independent regional advisory body guiding Africa’s eradication effort – called for urgent action to stop all forms of poliovirus affecting the continent. More here. SAGE and IHR EC reports published: the final reports of the April 2022 meeting of the Strategic Advisory Group of Experts on immunization (SAGE) and the June 2022 meeting of the IHR Emergency Committee on polio have been published online. This week, the Global Commission for Certification of Poliomyelitis Eradication (GCC) is meeting in-person in Geneva, to further review and evaluate global criteria for certification. Outcomes of the group’s meeting will be published in its report at www.polioeradication.org. nOPV2 rollout: Approximately 370 million doses of nOPV2 have been administered across 21 countries under its WHO Emergency Use Listing (EUL) to date. An additional 17 countries have met the requirements for nOPV2 use in the event of an outbreak. For more information on nOPV2, visit: www.polioeradication.org/nOPV2

Summary of new polioviruses this week:
– Pakistan: one WPV1 case and one positive environmental sample
– Benin: one cVDPV2 positive environmental sample
– Djibouti: two cVDPV2 positive environmental samples
– Niger: two cVDPV2 cases and one positive environmental sample
– Nigeria: one cVDPV2 case and one positive environmental sample
– Somalia: one cVDPV2 positive environmental sample
– Yemen: four cVDPV2 positive environmental samples

UN OCHA – Current Emergencies

Afghanistan
Afghanistan: Flash Update #4 Earthquake in Paktika and Khost Provinces, Afghanistan (26 June 2022)

Northern Ethiopia

Ukraine
Ukraine: Situation Report - Last updated: 29 June 2022
:: ...Although returns increased over the last month, some 6.27 million people are still internally displaced, and over 5.3 became refugees in European countries.
:: Despite challenges, humanitarians reached about 10.3 million people with life-saving assistance since the war started, an increase of 1.5 million people since last week
World Bank Board Approves New Fund for Pandemic Prevention, Preparedness and Response (PPR)

Quality of care in the COVID-19 context: a multi-country perspective

Call for experts: SAGE working group on Dengue - deadline 31 July 2022

WHO and ANRS Emerging Infectious Diseases strengthen their collaboration in the area of HIV, viral hepatitis and sexually transmitted infections

WHO Director-General's opening remarks at the media briefing – 29 June 2022

WHO Director-General's remarks at G7 Leaders Summit – 27 June 2022

PAHO and Unitaid launch collaboration to advance the elimination of mother-to-child transmission of Chagas disease

Geneva/Washington DC, 30 June 2022 – The Pan American Health Organization (PAHO) and Unitaid today launched a five-year, US$ 2.6 million partnership to scale-up regional and national efforts to
eliminate mother-to-child transmission of Chagas disease. Chagas is a neglected tropical disease endemic to Latin America, where it kills more people than...

:: 29 Jun 2022
**As COVID-19 cases continue to rise in the Americas, many are at risk of developing post-COVID condition**

While much remains unknown about the impact of this condition, health systems must prepare for the long-term, says PAHO Director. Washington D.C. 29 June 2022 (PAHO) – As COVID-19 cases continue to rise in the Americas, with new infections increasing by 13.9% from last week, Pan American Health Organization (PAHO) Director, Carissa F. Etienne...

**WHO South-East Asia Region SEARO**
*No new digest content identified.*

**WHO European Region EURO**
:: 1 July 2022  News release  **New report highlights the impact of changes in environment on One Health**
:: 1 July 2022  Statement  **Statement - No room for complacency**

**WHO Eastern Mediterranean Region**  EMRO
:: Protecting children from measles in drought-affected Somalia  26 June 2022

**WHO Western Pacific Region**
:: 28 June 2022  Reaching the unreached with COVID-19 vaccination across the Western Pacific Region

::::

**Disease Outbreak News (DONs)**
*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

27 June 2022 | **Multi-country monkeypox outbreak: situation update**

*Outbreak at a glance*
Since 1 January and as of 22 June 2022, 3413 laboratory confirmed cases and one death have been reported to WHO from 50 countries/territories in five WHO Regions.

Since the previous **Disease Outbreak News of 17 June** was published, 1310 new cases have been reported and eight new countries have reported cases...

::::

**WHO Events**
https://www.who.int/news-room/events/1
[Selected]

**11th ACT-Accelerator Facilitation Council meeting**
6 July 2022 12:30 – 15:00 UTC Time

**Enhanced use of data to monitor safety and effectiveness of paediatric medicines**
6 July 2022 15:00 – 16:30 CET
New WHO Publications
https://www.who.int/publications/i

Selected Titles
30 June 2022
Emergency in Ukraine: external situation report #16, published 30 June 2022: reporting period: 16–29...

30 June 2022
Vector control and the elimination of gambiense human African trypanosomiasis (HAT) - Joint FAO/WHO Virtual...

28 June 2022
Public health advice for gatherings during the current monkeypox outbreak

28 June 2022
WHO compendium of innovative health technologies for low-resource settings 2022

CDC/ACIP [U.S.] [to 02 July 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases

CDC Director Adopts Preference for Specific Flu Vaccines for Seniors
Thursday, June 30, 2022
CDC Director Rochelle P. Walensky, M.D., M.P.H., adopted the Advisory Committee on Immunization Practices’ (ACIP) recommendation to preferentially recommend the use of specific flu vaccines for adults 65 years and older, including higher dose and adjuvanted flu vaccines. The preference applies to Fluzone High-Dose Quadrivalent, Flublok Quadrivalent and Fluad Quadrivalent flu vaccines.

CDC Activates Emergency Operations Center for Monkeypox Response
Tuesday, June 28, 2022

ACIP Meetings
Next ACIP Meeting
October 19-20

MMWR Weekly: Current Volume (71)
July 1, 2022 / No. 26
Updated U.S. Public Health Service Guideline for Testing of Transplant Candidates Aged <12 Years for Infection with HIV, Hepatitis B Virus, and Hepatitis C Virus — United States, 2022

COVID-19 Vaccine Provider Availability and Vaccination Coverage Among Children Aged 5–11 Years — United States, November 1, 2021–April 25, 2022

Interim Analysis of Acute Hepatitis of Unknown Etiology in Children Aged <10 Years — United States, October 2021–June 2022


Coronavirus Disease 2019 (COVID-19) — CDC

Approximately 15 announcements/reports/data summaries.

Africa CDC
http://www.africacdc.org/
News
Africa CDC organizes first training on Real-Time PCR-based Monkeypox virus (MPXV) testing for 20 African Union Member States
28 June 2022

Press Releases
Press Release on Monkeypox situation in Africa
27 June 2022

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China
http://en.nhc.gov.cn/
News
July 2: Daily briefing on novel coronavirus cases in China
On July 1, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 72 new cases of confirmed infections

National Medical Products Administration — PRC
http://english.nmpa.gov.cn/
News
Chinese mainland reports 12 new local confirmed COVID-19 cases
The Chinese mainland Thursday reported 12 locally-transmitted confirmed COVID-19 cases, nine of which were in Anhui province, the National Health Commission said Friday.

CCDC Weekly Reports: Current Volume (4)
2022-07-01 / No. 26  ENVIRONMENTAL HEALTH ISSUE
View  PDF of this issue
:: Preplanned Studies: Long-Term Temperature Variability and Risk of Dyslipidemia Among Middle-Aged and Elderly Adults: A Prospective Cohort Study — China, 2011–2018
:: Preplanned Studies: Independent and Interactive Effects of Environmental Conditions on Aerosolized Surrogate SARS-CoV-2 — Beijing, China, June to September 2020
:: Vital Surveillances: Interactive Effects Between Temperature and PM2.5 on Mortality: A Study of Varying Coefficient Distributed Lag Model — Guangzhou, Guangdong Province, China, 2013–2020

Organization Announcements

Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group  [to 02 July 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation  [to 02 July 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 02 July 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
European Vaccine Initiative  [to 02 July 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid  [to 02 July 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Selected Resources
No new digest content identified

Fondation Merieux  [to 02 July 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

Gavi  [to 02 July 2022]
https://www.gavi.org/
News Releases
No new digest content identified

GHIT Fund  [to 02 July 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified

Global Fund  [to 02 July 2022]
News & Stories
No new digest content identified

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]  [to 02 July 2022]
https://www.glopid-r.org/news/
News
No new digest content identified

Hilleman Laboratories  [to 02 July 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified

HHMI - Howard Hughes Medical Institute [to 02 July 2022]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project [to 02 July 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI [to 02 July 2022]
https://www.iavi.org/
Latest News
No new digest content identified.

ICRC [to 02 July 2022]
What’s New  [Selected]

**Bringing IHL Home through Domestic Law and Policy: Report**

The Fifth Universal Meeting of National Committees and Similar Entities on International Humanitarian Law (Universal Meeting), hosted by the International Committee of the Red Cross (ICRC), took place online between 29 November and 2 December 2021, u

28 June 2022

**Mozambique: 1 million people in conflict-affected regions receive two doses of the COVID-19 vaccine**

Mozambique’s national immunization campaign has vaccinated over 1 million people -- 75% of the population -- in six districts affected by armed conflict in the provinces of Cabo Delgado, Manica, and Sofala with the support of the International Commit

28-06-2022 | News release

**Committing to anti-personnel mine ban saves civilian lives**

This is a positive step for protecting people affected by conflict around the world as anti-personnel landmines continue to kill and maim even when a war is over.

27-06-2022 | Statement

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
Press Releases/Announcements
No new digest content identified.

**IFFIm**
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

**IFRC** [to 02 July 2022]
Press Releases [Selected]
28/06/2022
COVID-19: Red Cross Red Crescent turns to animation to boost global vaccine effort

28/06/2022
COVID-19: Nearly 1 billion still without any vaccination in Asia Pacific

28/06/2022
Millions in Bangladesh impacted by one of the worst floodings ever seen

**Institut Pasteur** [to 02 July 2022]
Press Documents
No new digest content identified.

**IOM / International Organization for Migration** [to 02 July 2022]
News 01 Jul 2022
IOM Deplores Deaths at Chad-Libya Border and Calls for Stronger Action for Migrant Protection

News 01 Jul 2022
Latest Migrant Tragedy in Texas Highlights Crisis Along Deadliest Migration Land Route

News 29 Jun 2022
IOM, UNHCR Call for Vigorous Investigation After Dozens Die in Abandoned Trailer in Texas

News 28 Jun 2022
Returns Increase in Ukraine, but 6.2 Million People Remain Internally Displaced

**ISC / International Science Council** [to 25 Jun 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils. No new digest content identified.

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC [to 02 July 2022]
Updates; Events
No new digest content identified.

IVI [to 02 July 2022]
http://www.ivi.int/
IVI News & Announcements
SK bioscience’s COVID-19 vaccine approved for use by Republic of Korea
The International Vaccine Institute (IVI) is pleased to congratulate SK bioscience, the Coalition for Epidemic Preparedness Innovations (CEPI), and other partners for the June 29, 2022 approval of SK bioscience’s COVID-19 vaccine (SKY Covione™) by the Ministry of Food and Drug Safety, Republic of Korea.

IVI goes to Sweden
This new office marks IVI’s first expansion since the founding of its headquarters in Seoul, Korea in 1997 as a UN treaty-based international organization.

Johns Hopkins Center for Health Security [to 02 July 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
Johns Hopkins Center for Health Security Releases Findings of Study Examining Feasibility of Establishing a New, Nongovernmental Health Security Center in Asia
June 27, 2022

MSF/Médecins Sans Frontières [to 02 July 2022]
http://www.msf.org/
Latest [Selected Announcements]
Nigeria
Urgent humanitarian response needed to avoid deadly consequences in Borno
Press Release 30 Jun 2022

South Sudan
Thousands at severe risk due to malnutrition and deadly diseases in Twic County
Voices from the Field 29 Jun 2022

Syria
Access to healthcare in northwest Syria at risk over potential border crossing closure
Project Update 29 Jun 2022

Mediterranean migration
At least 30 people feared dead after tragic rescue in the central Mediterranean
Press Release 28 Jun 2022

Burkina Faso
Enormous needs for hundreds of thousands of people displaced by ongoing conflict and insecurity
Project Update 27 Jun 2022

Afghanistan
Deadly earthquake in Khost and Paktika leaves hundreds killed and thousands injured
Project Update 27 Jun 2022

National Academy of Medicine - USA [to 02 Jul 2022]
hhttps://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 02 Jul 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 02 July 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 02 Jul 2022]
http://www.nih.gov/
News Releases
NIH-funded project offers efficient approach when tracking SARS-CoV-2 variants
June 29, 2022 — Comprehensive genotyping approach offers cost savings and near immediate reporting.

Trial of potential universal flu vaccine opens at NIH Clinical Center
June 28, 2022 — The study can enroll up to 100 people aged 18 to 55 years.
A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The placebo-controlled trial will test the safety of a candidate vaccine, BPL-1357, and its ability to prompt immune responses. The vaccine candidate was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The single-site trial can enroll up to 100 people aged 18 to 55 years and is led by NIAID investigator Matthew J. Memoli, M.D...
**OHCHR report: human rights interventions are indispensable to ending AIDS for everyone by 2030**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 02 July 2022]
Selected News Releases, Announcements
News Comment: **UNHCR’s Grandi welcomes developments on EU asylum reform, encourages further progress under Czech EU Presidency**
Statement attributed to the UN High Commissioner for Refugees, Filippo Grandi
28 Jun 2022

**UNICEF** [to 02 July 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
27 June 2022
**Staggering scale of grave violations against children in conflict revealed in new UNICEF analysis**
NEW YORK/GENEVA, 28 June 2022 – Between 2005 and 2020, the United Nations verified over 266,000 grave violations against children committed by parties to conflict in more than 30 conflict situations across Africa, Asia, the Middle East, and Latin America, UNICEF...

**Unitaid** [to 02 July 2022]
https://unitaid.org/
Featured News
01 July 2022
**Unitaid and the Government of Kenya strengthen collaborative partnership to advance global health goals**

01 July 2022
**PAHO and Unitaid launch collaboration to advance the elimination of mother-to-child transmission of Chagas disease**

**Vaccine Equity Cooperative [nee Initiative]** [to 02 July 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 02 July 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
Vaccine Confidence Project [to 02 July 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 02 July 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
Vaccine Providers Update
June 2022

Wellcome Trust [to 02 July 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
Opinion
Author: Lisa Heinrich
G7 progress against pandemic threats is promising – now they must act
1 July 2022

The Wistar Institute [to 25 Jun 2022]
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 02 July 2022]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

World Bank [to 02 July 2022]
Selected News, Announcements
World Bank Board Approves New Fund for Pandemic Prevention, Preparedness and Response (PPR)
World Bank to work together with WHO to set up Secretariat at the World Bank, with WHO as lead technical partner WASHINGTON, June 30, 2022— The devastating human, economic, and social cost of COVID-19...
Date: June 30, 2022 Type: Press Release
Fact Sheet: Financial Intermediary Fund for Pandemic Prevention, Preparedness and Response

Pandemic preparedness is a top global priority. With broad support from the G20, the World Bank Board of Directors approved the establishment of a Financial Intermediary Fund (FIF) on pandemic prevention...

Date: June 30, 2022 Type: Brief

Financing for Education Stagnant or Declining Despite Chronic Learning Needs Post-COVID-19

WASHINGTON, June 28, 2022—A new World Bank-UNESCO report released in time for the Transforming Education Pre-Summit taking place in Paris (June 28-30) shows that the COVID-19 pandemic has worsened existing...

Date: June 28, 2022 Type: Press Release

World Customs Organization – WCO [to 02 July 2022]
http://www.wcoomd.org/
Latest News
No new digest content identified.

World Organisation for Animal Health (OIE) [to 02 July 2022]
https://www.oie.int/en/
Press Releases, Statements
Use of antimicrobials in animals trends downwards, new report says
Published on 27 June 2022
World Organisation for Animal Health report shows promising trends in the race to fight antimicrobial resistance and preserve the efficacy of these critical medicines.

Paris, France – The use of antimicrobials in animals across the world has shown an overall decrease of 27%1 between 2016 and 2018, according to the data reported to the World Organisation for Animal Health (WOAH, founded as OIE).

Similar progress has been found in the use of antibiotics for growth promotion. For long a common way to enhance productivity in animals raised for human consumption, the use of antibiotics in healthy animals to boost growth is no longer a practice in nearly 70% of the reporting countries2...

...“In a world that is more globalised and interconnected than ever before, this is a positive step forward as it shows that a growing number of farmers, animal owners and animal health professionals worldwide are adapting their practices to use antimicrobials more prudently. These efforts contribute to protecting everyone’s health. But much more needs to be done to preserve our therapeutic options and overcome the spread of infectious diseases,” said Dr Monique Eloit, Director General of the World Organisation for Animal Health...

WTO - World Trade Organisation [to 02 July 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
Members welcome MC12 commitment to address dispute settlement
30 June 2022
At a meeting of the Dispute Settlement Body (DSB) on 30 June, WTO members took the floor to welcome the commitment made at the WTO’s 12th Ministerial Conference (MC12) to engage in discussions aimed at securing a fully functioning dispute settlement system by 2024.

**Summary of the meeting**

**Proposed items for consideration at the DSB**

---

**ARM [Alliance for Regenerative Medicine]** [to 02 July 2022]


Selected Press Releases

No new digest content identified.

**BIO** [to 02 July 2022]


Press Releases

No new digest content identified.

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 02 July 2022]

http://www.dcvmn.org/

News; Upcoming events

No new digest content identified.

**ICBA – International Council of Biotechnology Associations** [to 02 July 2022]

https://internationalbiotech.org/news/

News

No new digest content identified.

**IFPMA** [to 02 July 2022]

http://www.ifpma.org/resources/news-releases/

Selected Press Releases, Statements, Publications

**Policy brief: Regulatory agilities applied during COVID-19**

23 June 2022

**International Alliance of Patients’ Organizations – IAPO** [to 02 July 2022]

https://www.iapo.org.uk/news/topic/6

Press and media [Selected]

No new digest content identified.

**International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News
No new digest content identified.

**PhRMA** [to 02 July 2022]
http://www.phrma.org/
Latest News [Selected]
No new digest content identified.

::::::
::::::

**Vaccines/Therapeutics/Medicines - Developer/Manufacturer Announcements**

**AstraZeneca**
*Press Releases* - No new digest announcements identified

**Bharat Biotech**
*Press Releases*
Jun 17: [COVAXIN® demonstrates robust safety and immunogenicity in children 2-18 years](http://www.phrma.org/)

**Biontech**
*Press Releases*
**Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine**
29 June 2022
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses

**CanSinoBIO**
*News* - Website not responding at inquiry

**CIGB**
*Latest News* - No new digest announcements identified

**Cinnagen**
*Recent News* - No new digest announcements identified

**Clover Biopharmaceuticals** - China
*News*
Jun 27, 2022
**Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster**
**Curevac** [Bayer Ag – Germany]
*News* - No new digest announcements identified

**Gamaleya National Center**
*Latest News and Events* - See Russia below.

**GSK**
*Press releases for media*
28 June 2022 *Japan’s Ministry of Health, Labour and Welfare accepts Shingrix regulatory submission to prevent shingles in at-risk adults aged 18 years and older*

**IMBCAMS**, China
*Home* - Website not responding at inquiry

**Janssen/JNJ**
*Press Releases* - No new digest announcements identified

**Medicago**
*Media* - No new digest announcements identified

**Merck**
*News releases* - No new digest announcements identified

**Moderna**
*Press Releases* - No new digest announcements identified

**Nanogen**
*News* - No new digest announcements identified

**Novartis**
*News* - No new digest announcements identified

**Novavax**
*Press Releases*
Jul 1, 2022 *Statement*
**Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA**

Jun 28, 2022
**Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants**

**Pfizer**
*Recent Press Releases*
06.30.2022 *Press Releases*
**Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™ Medicines**
06.29.2022  Press Releases

**Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine**

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases  - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS  - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News  - No new digest announcements identified

Sinovac
Press Releases
SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa
2022/06/25

SK Biosciences
Press Releases
SK bioscience and GSK Announce Biologics License Application Approval of SKY Covione™ in Republic of Korea
SKY Covione™ will be ready to enter into domestic vaccine markets after passing the national lot rel...
2022.06.29

SK bioscience Marks Successful Completion of Global Forum to Prepare the Next Pandemic
· SK bioscience held the Global Forum to discuss about the Next Pandemic response strate...
2022.06.28

Valneva
Press Releases  - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology
Home  - No new digest announcements identified  [404 error]

WestVac Biopharma
Media  - No new digest announcements identified

Zhifei Longcom, China
World Bank Board Approves New Fund for Pandemic Prevention, Preparedness and Response (PPR)

World Bank to work together with WHO to set up Secretariat at the World Bank, with WHO as lead technical partner

WASHINGTON, June 30, 2022—The devastating human, economic, and social cost of COVID-19 has highlighted the urgent need for coordinated action to build stronger health systems and mobilize additional resources for pandemic prevention, preparedness, and response (PPR).

The World Bank’s Board of Executive Directors today approved the establishment of a financial intermediary fund (FIF) that will finance critical investments to strengthen pandemic PPR capacities at national, regional, and global levels, with a focus on low- and middle-income countries. The fund will bring additional, dedicated resources for PPR, incentivize countries to increase investments, enhance coordination among partners, and serve as a platform for advocacy. The FIF will complement the financing and technical support provided by the World Bank, leverage the strong technical expertise of WHO, and engage other key organizations.

Developed with leadership from the United States, and from Italy and Indonesia as part of their G20 Presidencies, and with broad support from the G20 and beyond, over $1 billion in financial commitments have already been announced for the FIF, including contributions from the United States, the European Union, Indonesia, Germany, the United Kingdom, Singapore, the Gates Foundation and the Wellcome Trust.
“I’m pleased by the broad support from our shareholders for a new Financial Intermediary Fund at the World Bank,” World Bank Group President David Malpass said. “The World Bank is the largest provider of financing for PPR with active operations in over 100 developing countries to strengthen their health systems. The FIF will provide additional, long-term funding to complement the work of existing institutions in supporting low- and middle-income countries and regions to prepare for the next pandemic.”

“Access to financing for pandemic prevention and preparedness is crucial. COVID-19 has exposed major gaps in preparedness capacities, which the Financial Intermediary Fund can address in a coherent manner, as part of the global architecture for health emergency preparedness and response,” said WHO Director General Dr Tedros Adhanom Ghebreyesus. “WHO will play a central role in the FIF, providing technical leadership for its work in close collaboration with the World Bank to realize this ambitious vision.”

The goal of the FIF is to provide financing to address critical gaps in pandemic PPR to strengthen country capacity in areas such as disease surveillance, laboratory systems, health workforce, emergency communication and management, and community engagement. It can also help address gaps in strengthening regional and global capacity, for example, by supporting data sharing, regulatory harmonization, and capacity for coordinated development, procurement, distribution and deployment of countermeasures and essential medical supplies.

In the coming weeks, the Bank and WHO will work closely with donors and other partners to develop the detailed scope and design of the FIF. The ongoing discussions will be informed by the extensive inputs provided through stakeholder engagement (LINK). The goal is to launch the FIF in fall 2022...

Fact Sheet: Financial Intermediary Fund for Pandemic Prevention, Preparedness and Response
Date: June 30, 2022 Type: Brief

:::
:::

Featured Journal Content

PNAS - Proceedings of the National Academy of Sciences of the United States
June 21, 2022 | vol. 119 | no. 25
Research Article June 13, 2022Coronavirus (COVID-19)
Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic

The fragmented and inefficient healthcare system in the United States leads to many preventable deaths and unnecessary costs every year. Universal healthcare could have alleviated the mortality caused by a confluence of negative COVID-related factors. Incorporating the demography of the uninsured with age-specific COVID-19 and nonpandemic mortality, we estimated that a single-payer universal healthcare system would have saved 212,000 lives in 2020 alone. We also
calculated that US$105.6 billion of medical expenses associated with COVID-19 hospitalization could have been averted by a Medicare for All system.

Abstract
The fragmented and inefficient healthcare system in the United States leads to many preventable deaths and unnecessary costs every year. During a pandemic, the lives saved and economic benefits of a single-payer universal healthcare system relative to the status quo would be even greater. For Americans who are uninsured and underinsured, financial barriers to COVID-19 care delayed diagnosis and exacerbated transmission. Concurrently, deaths beyond COVID-19 accrued from the background rate of uninsurance. Universal healthcare would alleviate the mortality caused by the confluence of these factors. To evaluate the repercussions of incomplete insurance coverage in 2020, we calculated the elevated mortality attributable to the loss of employer-sponsored insurance and to background rates of uninsurance, summing with the increased COVID-19 mortality due to low insurance coverage. Incorporating the demography of the uninsured with age-specific COVID-19 and nonpandemic mortality, we estimated that a single-payer universal healthcare system would have saved about 212,000 lives in 2020 alone. We also calculated that US$105.6 billion of medical expenses associated with COVID-19 hospitalization could have been averted by a single-payer universal healthcare system over the course of the pandemic. These economic benefits are in addition to US$438 billion expected to be saved by single-payer universal healthcare during a nonpandemic year.

::: Featured Journal Content

Science
Volume 377| Issue 6601| 1 Jul 2022
https://www.science.org/toc/science/current
Editorial
Science, health, and truth
BY William L. Roper
30 Jun 2022
The past 2 years have been a strange and difficult time for the world. The COVID-19 pandemic has brought illness, hospitalization, and death near to many people. In the United States, people are divided not only on what they should do but also on what constitutes the facts.

Many are seemingly in an alternative world, driven by disinformation, conspiracy theories, and anti-science beliefs. How can health and medical leaders do their jobs while trying to cope with a polarized public? They must be more effective in explaining and persuading the public on matters of science and health. This will require better clarification of two things to the public—the roles of science and politics in public policy decisions, and the means by which scientific truth is established and updated.

There is a continuing strand of argument from many in the scientific community that “we ought to get politics out of public health.” And many politicians have said that scientists are not the ones to make public policy decisions related to public health or other issues. The reality is that both science and politics are essential for public health to work well. Scientists inform public understanding of the patterns of health and illness in populations, especially when epidemics and pandemics strike. And politics—the way decisions are made in a democratic society—is vital for acting on the
information and insights that the scientific community provides for the benefit of everyone.

In addition to clarifying the separate roles of science and politics, society needs to understand better how scientific truth is established and updated. It is based on verified and reproducible facts. The scientific method of gathering data, debating various formulations of the information, and arriving at consensus understandings of what is “true” about a particular matter has been the bedrock for establishing scientific truth for centuries. But in the past few years, political leaders, media personalities, and ordinary citizens have proclaimed their own “alternative facts,” disparaging the idea that anyone should question their “facts” and theories.

In his recent book, *The Constitution of Knowledge: A Defense of Truth*, Jonathan Rauch clearly and convincingly describes and defends the Enlightenment-born process of weighing evidence and committing to truth. He explains that the endeavor is founded on two arguments: The truth is based on what is known so far and the truth applies to everyone. **Rauch argues that this has produced a process for certifying knowledge—a public system for adjudicating differences of belief and perception and for developing shared and warranted conclusions about truth. This system provides three public goods: knowledge (distinguishing reality from nonreality), freedom (encouraging rather than repressing human autonomy, creativity, and empowerment), and peace (rewarding social conciliation, maximizing the number of disagreements that are resolvable, and compartmentalizing and marginalizing disagreements that cannot be resolved).**

Given that truth is based on what is known so far, it is always provisional. We likely will know more tomorrow than today, and we will then have to revise our conclusions. That is just the scientific method at work. Though science and politics have separate roles, once this system “gets the facts straight,” scientists and political leaders can work constructively together for the common good.

**This knowledge-certifying system is under concerted attack today, most notably in polarized political conflicts**, including about masks and vaccines, climate change, and gun violence. Restoring confidence in messages regarding science for the public good will be challenging, but it can only be done if there is an effort to explain, defend, and reinforce this public system for shepherding new knowledge. This needs to include widespread discussions across the scientific community and in the public at large, leading to a broad recommitment to the scientific method.

The challenges of communicating messages about science, health, and truth are among the often-mentioned reasons for the fatigue and discouragement that public health and medical leaders face today. And that same frustration is transferred to those who seek to engage the wider public with these messages.

**Overcoming these challenges will surely be difficult, but with concerted effort it can be done, as it has before—for example, in efforts to promote widespread childhood immunizations. And this requires a never-ending commitment, as we are learning every day.**
Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study
Sheldrick, Kyle A. MBBS1,*; Meyerowitz-Katz, Gideon MPH2; Tucker-Kellogg, Greg PhD3
doi: 10.1097/MJT.0000000000001528

Abstract
Background: Multiple vaccines against Covid-19 have passed through phase-3 trials; however, concerns have been raised about alleged excessive similarity of efficacy across age groups for the Sputnik V vaccine.
Study Question: How likely are the observed efficacies for all age subgroups to fall within the range of by-age efficacies claimed for the AstraZeneca, Janssen, Moderna, Pfizer, and Sputnik V vaccines, assuming that there is no effect of age on efficacy?
Study Design: We performed a simulation study using R of 1000 and then 50,000 simulated trials for each vaccine, with random allocation to each arm but fixed enrollment numbers by age group. We used study-wide efficacy and infection rate for all age groups. We recorded the observed vaccine efficacies in each age group and summated how many simulations had all observed efficacies fall within the range of efficacies described in the relevant article.
Results: In the 1000-trial simulation for the AstraZeneca vaccine, in 23.8% of simulated trials, the observed efficacies of all age subgroups fell within the efficacy bounds for age subgroups in the published article. The J + J simulation showed 44.7%, Moderna 51.1%, Pfizer 30.5%, and 0.0% of the Sputnik simulated trials had all age subgroups fall within the limits of the efficacy estimates described by the published article. In 50,000 simulated trials of the Sputnik vaccine, 0.026% had all age subgroups fall within the limits of the efficacy estimates described by the published article, whereas 99.974% did not.
Conclusions: The distribution of alleged vaccine efficacies of the Sputnik vaccine by age in the phase-III trial is very unlikely to occur in genuine experimental data, even if the number of patients recruited, vaccine efficacy, and overall infection rate are true and there is no underlying difference in vaccine efficacy by age.

African Development Bank’s Board approves landmark institution: Establishment of African Pharmaceutical Technology Foundation to transform Africa’s pharmaceutical industry
27-Jun-2022 - The African Development Bank’s Board of Directors has approved the establishment of the African Pharmaceutical Technology Foundation, a new groundbreaking institution that will significantly enhance Africa’s access to the technologies that underpin the manufacture of medicines, vaccines, and other pharmaceutical products...

The African Pharmaceutical Technology Foundation...when fully established will be staffed with world-class experts on pharmaceutical innovation and development, intellectual property rights, and health policy; acting as a transparent intermediator advancing and brokering the interests of the African
pharmaceutical sector with global and other Southern pharmaceutical companies to share IP-protected technologies, know-how and patented processes.

African Development Bank Group President, Dr. Akinwumi Adesina said: “Even with the decision of the TRIPS Waiver at the World Trade Organization (WTO), millions are dying and will most likely continue to die from lack of vaccines and effective protection. The African Pharmaceutical Technology Foundation provides a practical solution and will help to tilt the access to proprietary technologies, knowledge, know-how and processes in favor of Africa”.

The World Trade Organization and the World Health Organization, respectively, welcomed and lauded the African Development Bank’s decision to establish the African Pharmaceutical Technology Foundation...

COVID Perspectives

S.Korea approves first domestically developed COVID vaccine

SEOUL, June 29 (Reuters) - South Korea approved its first domestically developed COVID-19 vaccine, manufactured by SK bioscience Co Ltd, for general public use following positive clinical data, authorities said on Wednesday.

The SKYCovione vaccine was authorised for a two-dose regimen on people aged 18 or older, with shots given four weeks apart, according to the Ministry of Food and Drug Safety.

In a phase III clinical trial of 4,037 adults, SKYCovione induced neutralizing antibody responses against the SARS-CoV-2 parental strain, SK bioscience said in a statement.

It is not yet known how effective it is against Omicron and other COVID variants.

The vaccine was jointly developed by the University of Washington's Institute for Protein Design, with the support of global drugmaker GlaxoSmithKline (GSK).

SK bioscience said it would seek authorisations for distribution of SKYCovione in other countries and through global vaccine sharing facility COVAX, and for emergency use listing at the World Health Organization...

Kenya to woo vaccine firms with tax offer

By EDWIN MUTAI
The East African
Thursday June 30 2022

Kenya has offered tax incentives to woo investors seeking to build factories for the manufacture of human vaccines including for Covid-19.

Investors with investments of at least Ksh10 billion ($85 million) will enjoy corporate and income taxes at exclusive rates to be negotiated with the government.

This is in line with changes to the law through the Finance Act, 2022 that President Uhuru Kenyatta signed into law last Friday.

Parliament amended the Income Tax Act, through the Finance Bill, 2022, to provide tax incentives to firms that will undertake local production of vaccines.

“A company which is engaged in business under a special operating framework arrangement with the government, incorporated for purposes of undertaking the manufacture of human vaccines, whose
capital investment is at least Sh10 billion, shall be subject to the rate of tax specified in the special operating framework arrangement with the government,” the Finance Act, 2022 states...

* * * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 2
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 7: E543-713 Jul 2022
https://journalofethics.ama-assn.org/issue/health-care-conflict-zones

Arts-Based Research in Health Care

Visual, musical, and poetic forms of creative expression have embodied healing in many cultures for millennia. Research methods based in these artistic forms have grown in prominence as the enterprise of health care has been led by kindred disciplines of bioethics and humanities to interrogate overmedicalization, to resist hyperfocus on measurability when the cost is neglect of narratives and experiences, and to recognize tendencies that too often privilege outcomes over processes. What we’ve learned is that medicine has much to learn from and contribute to the arts, and that the arts have much to learn from and contribute to medicine.

From the Editor

Arts-Based Research and Health Care
Mark Gilbert, PhD

Artistic or aesthetic ways of knowing have been embraced in many different cultures as forms of healing.1, 2 In health care and health professions education, there is increasing interest in the role of arts-based research or integrating the arts into a variety of clinical and community settings for therapeutic, educational, and expressive purposes.3, 4...

This special issue of the AMA Journal of Ethics presents myriad ways that artistic expression as a primary mode of inquiry can be used to nurture an inspiring medical education wherein creativity is embraced and can flourish.11 The clinicians, educators, artists, researchers, and students who contributed to this issue make clear how much health professionals and students can learn from engaging with artistic ways of knowing. Moreover, they testify to how the arts can be enriched and informed by health care. My experience of working in clinical contexts has taught me more about communication and silence. We hope this special issue creates opportunities for readers to witness the relationships and interactions fundamental to medicine and to grasp the profound challenges and
abundant rewards that await all who engage in arts-based research in clinical, public health, and community contexts.

**American Journal of Infection Control**  
June 2022  Volume 50  Issue 6  p593-716  
http://www.ajicjournal.org/current  
[Reviewed earlier]

**American Journal of Preventive Medicine**  
June 2022  Volume 62  Issue 6  p807-964  
https://www.ajpmonline.org/current  
[Reviewed earlier]

**American Journal of Public Health**  
June 2022  112(53)  
http://ajph.aphapublications.org/toc/ajph/current  
**Supplement 3 2022**  
**Public Health Nursing After COVID-19: Strengthening, Rebuilding, and Reimagining the System**  
This supplement issue of AJPH covers nursing and public health, offering insight into the importance of nurses during the COVID-19 pandemic as well as the future of nursing. Papers also engage with nursing and its intersection with climate change, vaccine readiness, community resilience, home visiting, and more. Additionally, images in this issue highlight a mobile produce market as well as a mural dedicated to the contributions of nurses from diverse backgrounds.

**American Journal of Tropical Medicine and Hygiene**  
Volume 106 (2022): Issue 6 (Jun 2022)  
https://www.ajtjmh.org/view/journals/tpmd/106/6/tpmd.106.issue-6.xml  
[Reviewed earlier]

**Annals of Internal Medicine**  
June 2022  Volume 175, Issue 6  
http://annals.org/aim/issue  
[Reviewed earlier]

**Artificial Intelligence – An International Journal**  
Volume 308  July 2022  
[New issue; No digest content identified]

**BMC Cost Effectiveness and Resource Allocation**
Facilitators and barriers of healthcare workers’ recommendation of HPV vaccine for adolescents in Nigeria: views through the lens of theoretical domains framework

The human Papillomavirus (HPV) vaccine has demonstrated efficacy in the prevention of cervical cancer when given in early adolescence. The recommendation of the vaccine by health care workers (HCW) is crucial...

Authors: Folusho M. Balogun and Olayemi O. Omotade
Citation: BMC Health Services Research 2022 22:824
Content type: Research Published on: 25 June 2022

Syndromic surveillance of respiratory-tract infections and hand hygiene practice among pilgrims attended Hajj in 2021: a cohort study

The risk of transmission of viral respiratory tract infections (RTIs) is high in mass gatherings including Hajj. This cohort study estimated the incidence of symptomatic RTIs and hand hygiene compliance with i...

Authors: Hashim A. Mahdi, Harunor Rashid, Fadi S. Qashqari, Sumyya H. Hariri, Osama A. Marglani, Osamah Barasheed, Aqel Albutti, Ameen S. Alwashmi, Ramon Z. Shaban, Robert Booy and Mohammad Alfelali
Citation: BMC Infectious Diseases 2022 22:578
Content type: Research Published on: 27 June 2022

Increasing incidence rates of sexually transmitted infections from 2010 to 2019: an analysis of temporal trends by geographical regions and age groups from the 2019 Global Burden of Disease Study

World Health Organization announced its goal of ending sexually transmitted infection (STI) epidemics by 2030. To provide a reference for tailored prevention strategies, we analyzed trends and differences in S...

Authors: Min Du, Wenxin Yan, Wenzhan Jing, Chenyuan Qin, Qiao Liu, Min Liu and Jue Liu
Citation: BMC Infectious Diseases 2022 22:574
Content type: Research Published on: 26 June 2022
Data privacy protection in scientific publications: process implementation at a pharmaceutical company

Sharing anonymized/de-identified clinical trial data and publishing research outcomes in scientific journals, or presenting them at conferences, is key to data-driven scientific exchange. However, when data from scientific publications are linked to other publicly available personal information, the risk of reidentification of trial participants increases, raising privacy concerns. Therefore, we defined a set of criteria allowing us to determine and minimize the risk of data reidentification. We also implemented a review process at Takeda for clinical publications prior to submission for publication in journals or presentation at medical conferences.

Authors: Friedrich Maritsch, Ingeborg Cil, Colin McKinnon, Jesse Potash, Nicole Baumgartner, Valérie Philippon and Borislava G. Pavlova  [Baxalta Innovations GmbH, A Takeda Company, Vienna, Austria]

Citation: BMC Medical Ethics 2022 23:65
Content type: Research Published on: 25 June 2022

Financing COVID-19 vaccination in sub-Saharan Africa: lessons from a nation-wide willingness to pay (WTP) survey in Ghana

Over 13 million doses of the coronavirus disease, 2019 (COVID-19) vaccines have been administered in Ghana as at March, 2022; 28.5% of the population have received one dose while 16.3% have been fully vaccinated...

Authors: Robert Kaba Alhassan, Edward Nketiah-Amponsah, Mustapha Immurana and Aaron Asibi Abuosi

Citation: BMC Public Health 2022 22:1273
Content type: Research Published on: 30 June 2022
The willingness of parents to vaccinate their children younger than 12 years against COVID-19: a cross-sectional study in Malaysia

The initiation of a new drug, for instance, the coronavirus disease 2019 (COVID-19) vaccine in children could be a source of major concern for parents. This study aims to determine the willingness of parents...

Authors: Diana-Leh-Ching Ng, Gin-Gin Gan, Chee-Shee Chai, Nur Adila Bt Anuar, Woweham Sindeh, Wei-Jing Chua, Asri B. Said and Seng-Beng Tan

Citation: BMC Public Health 2022 22:1265

Content type: Research Published on: 29 June 2022

The minimal COVID-19 vaccination coverage and efficacy to compensate for a potential increase of transmission contacts, and increased transmission probability of the emerging strains

Mass immunization is a potentially effective approach to finally control the local outbreak and global spread of the COVID-19 pandemic. However, it can also lead to undesirable outcomes if mass vaccination res...

Authors: Biao Tang, Xue Zhang, Qian Li, Nicola Luigi Bragazzi, Dasantila Golemi-Kotra and Jianhong Wu

Citation: BMC Public Health 2022 22:1258

Content type: Research Published on: 27 June 2022

BMC Research Notes
http://www.biomedcentral.com/bmcreresnotes/content
(Accessed 02 July 2022)
[No new digest content identified]

BMJ Evidence-Based Medicine
June 2022 - Volume 27 - 3
https://ebm.bmj.com/content/27/3
[Reviewed earlier]

BMJ Open
June 2022 - Volume 12 - 6
https://bmjopen.bmj.com/content/12/6
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 100(6); 2022 Jun 1
https://www.ncbi.nlm.nih.gov/pmc/issues/409664/
[Reviewed earlier]
Cell
Jun 23, 2022  Volume 185 Issue 13  p2201-2390
https://www.cell.com/cell/current
[New issue; No digest content identified]

Child Care, Health and Development
Volume 48, Issue 4  Pages: 513-657  July 2022
https://onlinelibrary.wiley.com/toc/13652214/current
[New issue; No digest content identified]

Clinical Pharmacology & Therapeutics
Volume 111, Issue 6  Pages: 1175-1344  June 2022
[Reviewed earlier]

Clinical Therapeutics
June 2022  Volume 44 Issue 6  p825-926
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 19 Issue 3, June 2022
https://journals.sagepub.com/toc/ctja/19/3
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 02 July 2022]
[No new digest content identified]

Contemporary Clinical Trials
Volume 117  June 2022
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 3 / June 2022
https://www.liebertpub.com/toc/crispr/5/3
[Reviewed earlier]
Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
June 2022 - Volume 35 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[New issue; No digest content identified]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 2 Pages: 63-122 June 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 4, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 3 - June 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[New issue; No digest content identified]

Disasters
Volume 46, Issue 3 Pages: 587-852 July 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[New issue; No digest content identified]

EMBO Reports
Volume 23 Issue 6 7 June 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]
Emerging Infectious Diseases
Volume 28, Number 7—July 2022
http://wwwnc.cdc.gov/eid/

Synopses

**Vaccine Effectiveness during Outbreak of COVID-19 Alpha (B.1.1.7) Variant in Men’s Correctional Facility, United States** [PDF - 549 KB - 6 pages]
R. A. Silverman et al.

Epidemics
Volume 39 June 2022
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 3 Pages: 1-40 May–June 2022
https://onlinelibrary.wiley.com/toc/25782363/current

*Reviewing research app updates • Mental illness and IRB inclusiveness*
[Reviewed earlier]

Ethics & International Affairs
Spring 2022 (36.1) | March 10, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 22 Pages 1-104 (June 2022)
[Reviewed earlier]

The European Journal of Public Health
Volume 32, Issue 3, June 2022
https://academic.oup.com/eurpub/issue/32/3

*Editorial*

**Commercialization challenges open science**
Eero Lahelma, Ossi Rahkonen, Tea Lallukka
Covid-19

Interaction between science advice and policymaking in time of COVID-19: a French perspective
Camille Bruat, Elisabeth Monnet, Jean-Michel Azanowsky, Bernard Faliu, Zeina Mansour ...
European Journal of Public Health, Volume 32, Issue 3, June 2022, Pages 468–473,
https://doi.org/10.1093/eurpub/ckac008

Expert Review of Vaccines
Vol 21 (6) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 3  May/June 2022
https://www.foreignaffairs.com/issues/2022/101/3
[Reviewed earlier]

Foreign Policy
Spring 2022
https://foreignpolicy.com/the-magazine/?issue_id=411130839
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
Article
State Capacity and the Triple COVID-19 Crises: An International Comparison
Fernando de la Cruz, Sergio Tezanos & Rogelio Madrueño
Pages: 129-154
Published online: 18 May 2022

Genetics in Medicines
Volume 24, Issue 6  Pages A1-A10, 1165-1378 (June 2022)
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/24/issue/6
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 02 July 2022]
Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations

Type 2 diabetes (T2D) is a worldwide scourge caused by both genetic and environmental risk factors that disproportionately afflicts communities of color. Leveraging existing large-scale genome-wide association...

Authors: Tian Ge, Marguerite R. Irvin, Amit Patki, Vinodh Srinivasasainagendra, Yen-Feng Lin, Hemant K. Tiwari, Nicole D. Armstrong, Barbara Benoit, Chia-Yen Chen, Karmel W. Choi, James J. Cimino, Brittney H. Davis, Ozan Dikilitas, Bethany Etheridge, Yen-Chen Anne Feng, Vivian Gainer...

Citation: Genome Medicine 2022 14:70
Content type: Research Published on: 29 June 2022

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 10, No. 3 June 29, 2022
http://www.ghspjournal.org/content/current
[New issue; No digest content identified]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 02 July 2022]
[No new digest content identified]

Global Public Health
Volume 17, Issue 6 (2022)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 25 Jun 2022]
Leveraging WHO’s Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model
Authors: Solomon Owusu Sekyere, Ivana Škrnjug-Yudov, Ulysse Ateba Ngoa, Marcela Juárez Hernández, Onome T. Abiri, James P. Komeh, Markieu Janneh Kaira, Essa Marenah, Juwe Darnuwele Kercula, Keturah Smith, Olga Rassokhina, Heidi Meyer and Christoph Conrad
Content type: Research 20 June 2022

A stable, well-functioning and integrated national medicines regulatory system is a core component of health systems resilient against infectious disease outbreaks. In many low- and middle-income countries, however, sizable gaps exist in the emergency preparedness framework of national regulatory
RegTrain-VaccTrain is a project of Germany Ministry of Health’s Global Health Protection Programme that contributes to global efforts aimed at strengthening such regulatory systems by providing technical support and advice to partner NRAs. In this study, we probed the outputs of our capacity-strengthening activities for clinical trials oversight (CTO) to take stock of progress made and examine remaining priorities in order to provide specialized technical assistance in addressing them to improve operational readiness for emergencies.

Health and Human Rights
Volume 24, Issue 1, June 2022
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 3 - July 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 6, June 2022
https://academic.oup.com/heapol/issue/37/6
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 02 July 2022]
The predictors of COVID-19 mortality among health systems parameters: an ecological study across 203 countries

Health systems responsiveness is the key to addressing infectious disease threats such as pandemics. The paper outlines an assessment of health systems resilience by exploring the association of health systems and Global Health Security (GHS) parameters with case load and mortality resulting from COVID-19 across 203 countries using an ecological design.
Authors: Sutapa Bandyopadhyay Neogi, Shivam Pandey, G. S. Preetha and Sumant Swain
Citation: Health Research Policy and Systems 2022 20:75
Content type: Research Published on: 27 June 2022

Human Gene Therapy
Volume 33, Issue 11-12 / June 2022
https://www.liebertpub.com/toc/hum/33/11-12
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList

**Article**
*A study on the willingness and influencing factors of novel coronavirus vaccination among medical personnel in North China*
Jinqi Hao, Huimin Liu, Jihai Shi, Qiufeng Wang, Xiaoyou Su, Zhengyang Shi, Yanqin Yu, Bo Liu & Youlin Qiao
Article: 2031775
Published online: 04 Apr 2022

**Review**
*Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines*
Elham Jamshidi, Amirhossein Asgary, Paria Shafiekhani, Yasaman Khajeamiri, Kawthar Mohamed, Hadi Esmaily, Sahand Jamal Rahi & Nahal Mansouri
Article: 2037384
Published online: 13 Apr 2022

**Article**
*Vaccine hesitancy and receipt of mandatory and optional pediatric vaccines in Shanghai, China*
Mengdi Ji, Zhuoying Huang, Jia Ren & Abram L. Wagner
Article: 2043025
Published online: 23 Mar 2022

**Article Commentary**
*Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal—experience, challenges and lessons learnt*
Ashata Dahal, Mila Shakya, Dikshya Pant, Anup Adhikari, Rachel Colin-Jones, Katherine Theiss-Nyland, Andrew J. Pollard, Buddha Basnyat & Shrijana Shrestha
Article: 2043104
Published online: 03 Mar 2022

Public acceptability of COVID-19 vaccines and its predictors in Middle Eastern/North African (MENA) countries: a systematic review
Omid Dadras, SeyedAhmad SeyedAalinaghi, Amirali Karimi, Ahmadreza Shamsabadi, Sara Mahdiabadi, Parsa Mohammadi, Ava Amiri, Alireza Shojaei, Zahra Pashaei, Pegah Mirzapour, Kowsar Qaderi, Mehrzad MohsseniPour, Sanam Allilou, Esmaeil Mehraeen & Shayesteh Jahanfar
Article: 2043719
Published online: 23 Mar 2022

**Article**
Parents’ attitudes, knowledge and practice towards vaccinating their children against COVID-19: a cross-sectional study
Walid Al-Qerem, Abdel Qader Al Bawab, Alaa Hammad, Tasneem Jaber, Sawsan I Khdair, Haneen Kalloush, Jonathan Ling & Rami Mosleh
Article: 2044257
Published online: 03 Mar 2022

Evaluation of vaccination status of health care workers for recommended vaccines and their acceptance of SARS-CoV-2 vaccines
Pembe Derin Oygar, Ayşe Büyükçam, Zumrut Sahbudak Bal, Nazan Dağıc, Şefika Elmas Bozdemir, Adem Karbuz, Benhur Şerivan Çetin, Yalçın Kara, Ceren Çetin, Nevin Hatipoğlu, Haneen Kalloush, Jonathan Ling & Rami Mosleh
Article: 2044707
Published online: 17 Jun 2022

Acceptability for COVID-19 vaccination: perspectives from Muslims
Li Ping Wong, Haridah Alias, Megat Mohamad Amirul Amzar Megat Hashim, Hai Yen Lee, Sazaly AbuBakar, Ivy Chung, Zhijan Hu & Yulan Lin
Article: 2045855
Published online: 19 Apr 2022

A matter of trust: a qualitative comparison of the determinants of COVID-19 vaccine hesitancy in Taiwan, the United States, the Netherlands, and Haiti
Chia-Wen Wang, Erik Pieter de Jong, Joseymyrne Ashley Faure, Jaylynn Leigh Ellington, Chi-Hsin Sally Chen & Chang-Chuan Chan
Article: 2050121
Published online: 29 Mar 2022

Immunity
Jun 14, 2022 Volume 55 Issue 6 p925-1138
https://www.cell.com/immunity/current
Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 02 July 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 02 July 2022]
Environmental impacts of mass drug administration programs: exposures, risks, and mitigation of antimicrobial resistance
Mass drug administration (MDA) of antimicrobials has shown promise in the reduction and potential elimination of a variety of neglected tropical diseases (NTDs). However, with antimicrobial resistance (AMR) be...
Authors: Joanna K. Konopka, Pranab Chatterjee, Connor LaMontagne and Joe Brown
Citation: Infectious Diseases of Poverty 2022 11:78
Content type: Scoping Review Published on: 30 June 2022

Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks
Mass drug administration (MDA) is a strategy to improve health at the population level through widespread delivery of medicine in a community. We surveyed the literature to summarize the benefits and potential...
Authors: Robert J. Rolfe, Hassaan Shaikh and L. Gayani Tillekeratne
Citation: Infectious Diseases of Poverty 2022 11:77
Content type: Scoping Review Published on: 30 June 2022

International Health
Volume 14, Issue 3, May 2022
https://academic.oup.com/inthealth/issue/14/3
[Reviewed earlier]

International Human Rights Law Review
Volume 10 (2021): Issue 2 (Dec 2021)
https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol 9, No 5 (2022) May 2022
[Reviewed earlier]
Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel
Nitai Levy, MD; Jordanna H. Koppel, MD; Or Kaplan, MD; et al.
free access has active quiz
This study examines outcomes of multisystem inflammatory syndrome in children during the Alpha, Delta, and Omicron variant waves of the COVID-19 pandemic in Israel.

COVID-19 in 2022—The Beginning of the End or the End of the Beginning?
Carlos del Rio, MD; Preeti N. Malani, MD, MSJ
free access
This Viewpoint discusses how variants and subvariants of SARS-CoV-2 will affect the continually changing COVID-19 pandemic and the ways in which the spread of COVID-19 can be controlled.
Journal of Adolescent Health
June 2022 Volume 70 Issue 6 p839-1008
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 74 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 3, June 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-3
[Reviewed earlier]

Journal of Development Economics
Volume 157 June 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 3, July 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
June 2022 - Volume 76 - 6
https://jech.bmj.com/content/76/6
[New issue; No digest content identified]

Journal of Evidence-Based Medicine
Volume 15, Issue 1 Pages: 1-72 March 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 1, 2022
Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 2, May 2022
https://muse.jhu.edu(issue/47787)
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 3, June 2022
https://link.springer.com/journal/10903/volumes-and-issues/24-3
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 20, 2022 , Issue 2
https://www.tandfonline.com/toc/wimm20/current
Article
[Reviewed earlier]

Journal of Infectious Diseases
Volume 225, Issue 12, 15 June 2022
https://academic.oup.com/jid/issue/225/12
EDITORIAL COMMENTARY
Editor's Choice
Are We Ready for Maternal Respiratory Syncytial Virus Vaccination?
Emily W E M Phijffer, Louis J Bont
The Journal of Infectious Diseases, Volume 225, Issue 12, 15 June 2022, Pages 2053–2055,
https://doi.org/10.1093/infdis/jiab613

Journal of International Development
Volume 34, Issue 4  Pages: 693-930  May 2022
https://onlinelibrary.wiley.com/toc/10991328/current
Special Issue: Long run effects of Covid-19 on developing countries
Issue Edited by: Sanghamitra Bandyopadhyay, Krishna Vadlamannati
[Reviewed earlier]

Journal of Medical Ethics
June 2022 - Volume 48 - 6
Journal of Patient-Centered Research and Reviews  
Volume 9, Issue 2 (2022)  
https://institutionalrepository.aah.org/jpcrr/  
[Reviewed earlier]

Journal of Pediatrics  
July 2022  Volume 246  p1-294  
http://www.jpeds.com/current  
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice  
https://joppp.biomedcentral.com/  
[Accessed 02 July 2022]  
[No digest content identified]

Journal of Public Health Management & Practice  
May/June 2022 - Volume 28 - Issue 3  
https://journals.lww.com/jphmp/pages/currenttoc.aspx  
[Reviewed earlier]

Journal of Public Health Policy  
Volume 43, issue 2, June 2022  
[Reviewed earlier]

Journal of Refugee & Global Health  
Volume 4, Issue 1 (2021)  
https://ir.library.louisville.edu/rgh/  
[Reviewed earlier]

Journal of the Royal Society – Interface  
June 2022  Volume 19  Issue 191  
https://royalsocietypublishing.org/toc/rsif/current  
[Reviewed earlier]

Journal of Travel Medicine  
Volume 29, Issue 3, April 2022
The Lancet
Jul 02, 2022 Volume 400 Number 10345 p1-72, e1
https://www.thelancet.com/journals/lancet/issue/current
Articles
Effectiveness of interventions to improve drinking water, sanitation, and handwashing with soap on risk of diarrhoeal disease in children in low-income and middle-income settings: a systematic review and meta-analysis
Jennyfer Wolf, et al.
Open Access

The Lancet Child & Adolescent Health
Jul 2022 Volume 6 Number 7 p445-508, e21
https://www.thelancet.com/journals/lanchi/issue/current
Articles
[Reviewed earlier]

Lancet Digital Health
Jun 2022 Volume 4 Number 6 e398-e476
https://www.thelancet.com/journals/landig/issue/current
Articles
[Reviewed earlier]

Lancet Global Health
Jun 2022 Volume 10 Number 6 e773-e926
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Jun 2022 Volume 22 Number 6 p743-912, e159-e182
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
The US Supreme Court abortion verdict is a tragedy. This is how research organizations can help

In response to the demise of Roe v. Wade, universities and research organizations can support those affected, ensure education and research on abortion continue and advocate for evidence-based policy.

Knock-in on CRISPR’s door

Interest is growing in genome-editing tools that can insert large chunks of DNA into the genome — and avoid the double-strand breaks associated with CRISPR–Cas9 genotoxicity
Features

The Worldview national ranking of health biotech sectors
John Hodgson
Deanna Schreiber-Gregory

Review Article 09 May 2022
The clinical progress of mRNA vaccines and immunotherapies
Anderson and colleagues discuss the progress and challenges of using mRNA for vaccines and immunotherapy.
Ann J. Barbier, Allen Yujie Jiang, Daniel G. Anderson

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 02 July 2022)
[No new digest content identified]

Nature Genetics
Volume 54 Issue 6, June 2022
https://www.nature.com/ng/volumes/54/issues/6
[Reviewed earlier]

Nature Human Behaviour
Volume 6 Issue 6, June 2022
https://www.nature.com/nathumbehav/volumes/6/issues/6
[New issue; No digest content identified]

Nature Medicine
Volume 28 Issue 6, June 2022
https://www.nature.com/nm/volumes/28/issues/6
[Reviewed earlier]

Nature Reviews Genetics
Volume 23 Issue 6, June 2022
https://www.nature.com/nrg/volumes/23/issues/6
[Reviewed earlier]

Nature Reviews Immunology
Volume 22 Issue 6, June 2022
https://www.nature.com/nri/volumes/22/issues/6
[Reviewed earlier]
Perspective


G. Persad and A. Pandya

... Although policymakers and investigators still struggle to quantify and compare the effects of various Covid-related interventions, we are steadily amassing data that could help inform choices. The pandemic’s medical, social, and economic harms have been immense, and they warrant a continuous policy response. All decision makers use some type of mental model to weigh the pros and cons of various policy options. Rigorous economic evaluation formalizes this process. Value judgments will still be required, but economic evaluation can make the decision-making process more systematic, comprehensive, and transparent.

---

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analysis Type</strong></td>
</tr>
<tr>
<td>Cost</td>
</tr>
<tr>
<td>Comparative-effectiveness</td>
</tr>
<tr>
<td>Cost-consequence</td>
</tr>
<tr>
<td>Cost-effectiveness</td>
</tr>
<tr>
<td>Benefit-cost</td>
</tr>
<tr>
<td>Extended cost-effectiveness</td>
</tr>
<tr>
<td>Distributional cost-effectiveness</td>
</tr>
</tbody>
</table>

* HVAC denotes heating, ventilation, and air conditioning, QALY quality-adjusted life-year, and DALY disability-adjusted life-year.
Impact of mandatory vaccination against serogroup C meningococci in targeted and non-targeted populations in France

Samy Taha, Muhamed-Kheir Taha & Ala-Eddine Deghmane

Abstract

Since January 2018, mandatory vaccination against meningococci serogroup C has been implemented in France for children <2 years with a recommended catch-up vaccination until the age of 24 years. We aimed to analyse the impact of mandatory vaccination on populations not targeted by it (2–24 years old). We used the database of the national reference centre for meningococci to collect the number of invasive meningococcal disease (IMD) cases before (2016–2017) and after (2018–2019) the mandatory vaccination. The cultured isolates were sequenced and submitted for genomic comparison. The total number of cases was 1706, including 376 cases of IMD serogroup C. Mandatory vaccination correlated with a significant decrease among the <2 years old and a decreasing trend among the 2–14 years old group but not among 15–25 years of age. This observation may be explained by the vaccine coverage that is still low among adolescents and young adults. Moreover, the genomic analysis revealed the co-circulation of two major genotypes belonging to the clonal complex ST-11 whose distribution differed across the age groups in accord with cyclic variations of genotypes. It is important to increase specific knowledge on meningococcal epidemiology and vaccination to involve them in establishing the vaccination strategy.
PLoS Medicine
http://www.plosmedicine.org/
(Accessed 02 July 2022)
Perspective
Addressing the impacts of COVID-19 on refugee health
Rebecca F. Grais, Emmanuel Baron
| published 27 Jun 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004050

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 02 July 2022)
Artificial intelligence in differentiating tropical infections: A step ahead
Shreelaxmi Shenoy, Asha K. Rajan, Muhammed Rashid, Viji Pulikkel Chandran, Pooja Gopal Poojari, Vijayanarayana Kunhikatta, Dinesh Acharya, Sreedharan Nair, Muralidhar Varma, Girish Thunga
Research Article | published 30 Jun 2022 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0010455

Conclusion
This is a first of its kind study where both statistical and machine learning approaches were explored simultaneously for differentiating tropical infections. Machine learning techniques in healthcare sectors will aid in early detection and better patient care.

Author summary
Distinguishing tropical infections is difficult due to its homogeneous nature from clinical and laboratory presentations among them. This is a first of its kind study where both statistical and machine learning approaches were explored simultaneously for differentiating tropical infections. Dengue, malaria, leptospirosis and scrub typhus were the common tropical infections in our settings as per the need analysis. Better predictors in terms of laboratory parameters and clinical presentations were identified from retrospective analysis and used for the regression and machine learning models. The parameters such as accuracy, true positive rate/sensitivity/recall, false positive rate, precision/positive predictive value, F-measure and ROC area for both the training and validation sets (10-fold cross validation) for all modelling approaches and diseases (One vs One and One vs others) were calculated. All the models observed to have an acceptable range of model performance in differentiating tropical infections. Albumin can be considered as the main parameter in differentiating these tropical infections. These models should be implemented in daily clinical routine practice via mobile or desktop assisted applications or tools.

PLoS One
http://www.plosone.org/
[Accessed 02 July 2022]
Research Article
Genomic surveillance of SARS-CoV-2 in patients presenting neurological manifestations
Anna Vicco, Francesca Caccuri, Serena Messali, Adriana Vitiello, Aron Emmi, Claudia Del Vecchio, Alberto Reale, Arnaldo Caruso, Giancarlo Ottaviano, Carla Mucignat, Cristina Parolin, Angelo Antonini, Arianna Calisti
Research Article | published 30 Jun 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270024

Covid-19 vaccination intentions among literate Ghanaians: Still the need to dissipate fear and build trust on vaccine efficacy?
Joseph Agebase Awuni, Michael Ayamga, Gilbert Dagunga
Research Article | published 29 Jun 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270742

Knowledge, attitude, and hesitancy towards COVID-19 vaccine among university students of Bangladesh
Research Article | published 27 Jun 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270684

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 02 July 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
June 21, 2022 | vol. 119 | no. 25
Commentary June 10, 2022
Closing the loop on crowdsourced science
James M. Robson and Alexander A. Green

Research Article June 13, 2022Coronavirus (COVID-19)
Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic
The fragmented and inefficient healthcare system in the United States leads to many preventable deaths and unnecessary costs every year. During a pandemic, the lives saved and economic benefits of a single-payer universal healthcare system relative to the ...
Alison P. Galvani, Alyssa S. Parpia, [...]Meagan C. Fitzpatrick
[See COVID Perspectives above for detail]

Research Article June 17, 2022
The societal responses to COVID-19: Evidence from the G7 countries
This paper provides a picture of how societies in the G7 countries have responded to the COVID-19 pandemic. Our point of departure is to examine the effects of the pandemic in terms of four fundamental normative sources for well-being: Solidarity (S; ... Katharina Lima de Miranda and Dennis J. Snower
Dynamics of cross-platform attention to retracted papers

Retracted papers often circulate widely on social media, digital news, and other websites before their official retraction. The spread of potentially inaccurate or misleading results from retracted papers can harm the scientific community and the public. ...

Hao Peng, Daniel M. Romero and Emőke-Ágnes Horvát
Research Ethics
Volume 18 Issue 3, July 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 02 July 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 42, Issue 6  Pages: 1149-1364  June 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Bayesian Networks for Risk Analysis and Decision Support
[New issue; No digest content identified]

Risk Management and Healthcare Policy
[Accessed 02 July 2022]
[No new digest content identified]

Science
Volume 377| Issue 6601| 1 Jul 2022
https://www.science.org/toc/science/current
Editorial
Science, health, and truth
BY William L. Roper
30 Jun 2022
[See Milestones above for full text]

Science and Engineering Ethics
Volume 28, issue 3, June 2022
The fight against malaria: Diminishing gains and growing challenges
BY Justin M. Cohen, Fredros Okumu, Bruno Moonen
29 Jun 2022

New approaches are needed to fight malaria given rapid population growth in high-endemic areas compounded by increasing prices for current tools.

Abstract
Since the year 2000, historic reductions in malaria incidence and mortality have been driven by the widespread distribution of bed nets, drugs, and insecticides for the prevention and treatment of malaria. Scale-up of these tools has been enabled by an increase in malaria financing compounded by price reductions, yet these trends are unlikely to continue at the same rate. Rapid population growth in high-endemic areas requires procurement of more of these tools just to maintain current coverage, even as prices are likely to increase as resistance to drugs and insecticides forces shifts to newer products. Further progress toward the long-term goal of malaria eradication requires a combination of greater funding, more cost-effective resource allocation, and fundamental changes to the global malaria control strategy.
**Vaccine**
Volume 40, Issue 26  Pages 3483-3720 (9 June 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/26

*Editorial*

**John D. Bailey retiring after more than 20 years of service to Vaccine**
Gregory A. Poland, Nicolette van Dijk
Page 3483

*Conference info Full text access*

**Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop**
Eloise Williams, Kathrine Craig, Christopher Chiu, Hugh Davies, ... Naho Yamazaki
Pages 3484-3489

*Conference info Open access*

**WHO working group meeting to amend WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines**
Javier Martin, Alan David Thomas Barrett, Dianliang Lei, Philip Minor
Pages 3490-3494

*Conference info Full text access*

**Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting**
Rajinder Kumar Suri, Benoit Hayman, Sai D. Prasad, Morena Makhoana, Patrick Tippoo
Pages 3495-3505

*Discussion Full text access*

**Building population and health system resilience: Using lessons learned during the COVID pandemic to implement life-course immunisation policy**
Sandra Evans, Daphné Holt, Catherine Weil-Olivier, Gary Finnegan, Vytautas Usonis
Pages 3511-3513

*Discussion Open access*

**Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization**
Daniel R. Feikin, Laith J. Abu-Raddad, Nick Andrews, Mary-Ann Davies, ... Minal K. Patel
Pages 3516-3527

*Review article Abstract only*

**Regulatory considerations for study of infant protection through maternal immunization**
Jane Namangolwa Mutanga, Barbee I. Whitaker, Richard A. Forshee
Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru
Abraham De-Los-Rios-Pinto, Daniel Fernandez-Guzman, David R. Soriano-Moreno, Lucero Sangster-Carrasco, ... Jose Gonzales-Zamora
Pages 3566-3572

Building leadership and management competencies of national immunization teams in 16 Gavi-eligible countries through the EPI leadership and management programme
Lynka Ineza, Kali Bechtold, Aziza Mwisongo, Sylvie Kwedi Nolna, Erika L. Linnander
Pages 3581-3587

Inequalities in the prevalence of full immunization coverage among one-year-olds in Ghana, 1993–2014
Eugene Budu, Bright Opoku Ahinkorah, Joshua Okyere, Abdul-Aziz Seidu, Henry Ofori Duah
Pages 3614-3620

A comparison of national vaccination policies to prevent serogroup B meningococcal disease
Giorgia Sulis, Miranda Horn, Ray Borrow, Nicole E. Basta
Pages 3647-3654

COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality
Walaa Abu Alya, Beesan Maraqa, Zaher Nazzal, Mahmoud Odeh, ... Mousa Aabed
Pages 3713-3719

Value in Health
June 2022 Volume 25 Issue 6 p869-1062
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

Pre-Print Servers
Gates Open Research
https://gatesopenresearch.org/browse/articles
Selected Research
Research Article metrics AWAITING PEER REVIEW
Regional clustering and waves patterns due to COVID-19 by the index virus and the lambda/gamma, and delta/omicron SARS-CoV-2 variants in Peru [version 1; peer review: awaiting peer review]
Melissa Toyama, Lucía Vargas, Sofía Ticlahuanca, Antonio M Quispe
Peer Reviewers Invited
PUBLISHED 01 Jul 2022

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

Selected Research

Changing patterns in reporting and sharing of review data in systematic reviews with meta-analysis of the effects of interventions: a meta-research study from the REPRiSE project
Phi-Yen Nguyen, Raju Kanukula, Joanne E McKenzie, Zainab Alqaidoom, Sue E Brennan, Neal R Haddaway, Daniel G Hamilton, Sathya Karunananthan, Steve McDonald, David Moher, Shinichi Nakagawa, David Nunan, Peter Tugwell, Vivian A Welch, Matthew J Page
medRxiv 2022.04.11.22273688; doi: https://doi.org/10.1101/2022.04.11.22273688 Revision

The 1968 Influenza Pandemic and COVID-19 Outcomes
Charles A Taylor, Christopher Boulos, Matthew J Memoli
medRxiv 2021.10.23.21265403; doi: https://doi.org/10.1101/2021.10.23.21265403 Revision

Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa
medRxiv 2022.06.28.22276983; doi: https://doi.org/10.1101/2022.06.28.22276983 Revision

COVID-19 Vaccine Hesitancy in Ghana: The Roles of Political Allegiance, Misinformation Beliefs, and Sociodemographic Factors
Ken Brackstone, Kirchuffs Atengble, Michael G Head, Laud A Boateng
medRxiv 2022.03.16.22272463; doi: https://doi.org/10.1101/2022.03.16.22272463 Revision
The Citation of Retracted COVID-19 Papers is Common and Rarely Critical
Gideon Meyerowitz-Katz, Praba Sekhar, Lonni Besançon, Tari Turner, Steve McDonald
medRxiv 2022.06.30.22277084; doi: https://doi.org/10.1101/2022.06.30.22277084

Abstract
Background
Retraction is the final safeguard against research error/misconduct. In principle, retraction exists to prevent serious issues identified in published research through post-publication review. Our study investigated the citing of clinical research papers retracted during the COVID-19 pandemic.

Methods
We used the Retraction Watch database extracted as of 27/01/2022 to identify retracted COVID-19 papers and the Google Scholar citation function to gather a dataset of citations of retracted clinical research. We reviewed key aspects of the citing research.

Results
In total, the Retraction Watch database included 212 entries for retracted COVID-19 papers. Of these, 53 papers were clinical. There were a total of 1,141 citations of retracted papers, with 105 errors, leaving 1,036 citations to analyze. The majority (86%) of citations were not critical. The majority (80%) of papers citing retracted research were published after the retraction date.

Conclusions
The citation of retracted and withdrawn COVID-19 clinical studies is common, and rarely critical. Most researchers who cite retracted research do not identify that the paper is retracted, even when submitting long after the paper has been withdrawn. This has serious implications for the reliability of published research and the academic literature, which need to be addressed.

Influenza and pneumococcal vaccination and the risk of COVID-19: A systematic review and meta-analysis
Georgia V Kapoula, Konstantina E Vennou, Pantelis G Bagos
medRxiv 2022.06.30.22277089; doi: https://doi.org/10.1101/2022.06.30.22277089

Limitations of models for guiding policy in the COVID-19 pandemic
Paul M McKeigue, Simon N Wood
medRxiv 2022.06.30.22277091; doi: https://doi.org/10.1101/2022.06.30.22277091

Deep Learning for Rare Disease: A Scoping Review
Junghwan Lee, Cong Liu, Junyoung Kim, Zhehuan Chen, Yingcheng Sun, James R. Rogers, Wendy K. Chung, Chunhua Weng
medRxiv 2022.06.29.22277046; doi: https://doi.org/10.1101/2022.06.29.22277046

Assessing transmission risks and control strategy for monkeypox as an emerging zoonosis in a metropolitan area
Pei Yuan, Yi Tan, Liu Yang, Elena Aruffo, Nicholas H. Ogden, Jacques Bélair, Jane Heffernan, Julien Arino, James Watmough, Hélène Carabin, Huaping Zhu
medRxiv 2022.06.28.22277038; doi: https://doi.org/10.1101/2022.06.28.22277038

Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies
Cathrine Axfors, Angelo Maria Pezzullo, Despina G. Contopoulos-Ioannidis, Alexandre Apostolatos, John P.A. Ioannidis
Establishing a core set of open science practices in biomedicine: a modified Delphi study
medRxiv 2022.06.27.22276964; doi: https://doi.org/10.1101/2022.06.27.22276964

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: safety and parasite growth dynamics
medRxiv 2022.06.27.22276860; doi: https://doi.org/10.1101/2022.06.27.22276860

Digitalization impacts the COVID-19 pandemic and the stringency of government measures
Helen Heinrichs, Florian Mueller, Lucia Rohfleisch, Volkmar Schulz, Steven R. Talbot, Fabian Kiessling
medRxiv 2022.06.27.22276377; doi: https://doi.org/10.1101/2022.06.27.22276377

Modelling Vaccination Strategies for the Control of Marburg Virus Disease Outbreaks
George Y Qian, W. John Edmunds, Daniel G Bausch, Thibaut Jombart
medRxiv 2022.06.17.22276538; doi: https://doi.org/10.1101/2022.06.17.22276538 Revision

Concurrent malaria and dengue fever in (sub-)Saharan Africa: a systematic review and meta-analysis
Tewelde T. Gebremariam, Zeleke Mekonnen, Jonas B. Danquah
medRxiv 2022.05.24.22275526; doi: https://doi.org/10.1101/2022.05.24.22275526 Revision

The Pandemic Response Commons
Matthew Trunnell, Casey Frankenberger, Bala Hota, Troy Hughes, Plamen Martinov, Urmila Ravichandran, Nirav S. Shah, Robert L. Grossman, The Pandemic Response Commons Consortium
medRxiv 2022.06.20.22276542; doi: https://doi.org/10.1101/2022.06.20.22276542

Wellcome Open Research [to 02 July 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 02 July 2022]
Selected Research
No new digest content identified.
**Think Tanks**

**Brookings**  [to 02 July 2022]
http://www.brookings.edu/
Accessed 02 July 2022

*Latest Research*

*Global Economy*

**Antimicrobial resistance: Designing a comprehensive macroeconomic modeling strategy**
Roshen Fernando and Warwick J. McKibbin
Thursday, June 30, 2022

**Center for Global Development**  [to 25 Jun 2022]
https://www.cgdev.org/

*Research [Selected]*

*WORKING PAPERS*

**Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures for Antimicrobials**
Anthony McDonnell et al.
June 28, 2022

This working paper aims to synthesise existing research and thinking on how antimicrobials are procured and ways to improve the current purchasing system.

**Chatham House**  [to 02 July 2022]
https://www.chathamhouse.org/
Accessed 02 July 2022

[No new digest content identified]

**CSIS**  [to 02 July 2022]
https://www.csis.org/
Accessed 02 July 2022

[No new digest content identified]

**Kaiser Family Foundation**
https://www.kff.org/search/?post_type=press-release
Accessed 02 July 2022

[No new digest content identified]

**ODI [Overseas Development Institute]**  [to 02 July 2022]

*Publications*

Accessed 02 July 2022

[No new digest content identified]
**Rand** [to 25 Jun 2022]
https://www.rand.org/pubs.html
[No new digest content identified]

**Urban Institute** [to 02 Jul 2022]
https://www.urban.org/publications

*New Research Publications*

*Testimony*

**Disparate Impacts of the COVID-19 Pandemic Across Race and Ethnicity in the Housing Market**
June 29, 2022

**World Economic Forum** [to 02 Jul 2022]
https://agenda.weforum.org/news/

*Media [Selected]*

**World Economic Forum Releases Blueprint for Equitable and Inclusive AI**

*News* 29 Jun 2022

- The number of initiatives advancing equity and inclusion has increased substantially over the past decades.
- Technology companies have an added complexity for equity and inclusion challenges unique to the design, development, deployment and use of technologies such as artificial intelligence (AI).
- This report paints a comprehensive picture of challenges and opportunities for improvements in equity and inclusion across the AI development life cycle and governance ecosystem.
- Read the framework [here](https://agenda.weforum.org/news/)

* * * * *

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there*
should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation, The Rockefeller Foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.